Artelo Biosciences (ARTL) Restructuring Costs (2024 - 2025)
Artelo Biosciences (ARTL) posted quarterly Restructuring Costs of $310000.0 for Q4 2025, down 16.89% year-over-year from $373000.0 in Q4 2024, and down 6.63% quarter-over-quarter from $332000.0 in Q3 2025.
Artelo Biosciences (ARTL) Restructuring Costs (2024 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Restructuring Costs for 2 consecutive years, with $310000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Restructuring Costs fell 16.89% year-over-year to $310000.0; the TTM figure through Dec 2025 stood at $1.2 million (down 7.65% YoY), while the FY2025 annual figure was $1.2 million, down 7.65% from the prior year.
- Restructuring Costs declined to $310000.0 in Q4 2025 per ARTL's latest filing, from $332000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $373000.0 in Q4 2024 and bottomed at $249000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Artelo Biosciences | 111,698.23 | -488,301.77 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 310,000.00 |
| Sep 30, 2025 | 332,000.00 |
| Jun 30, 2025 | 249,000.00 |
| Mar 31, 2025 | 317,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Sep 30, 2024 | 326,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 309,000.00 |